# QuidelOrtho Corporation – Consensus ‘buy’ rating and 22.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/quidelortho-corporation-consensus-buy-rating-and-22-5-upside-potential/4121184537
- Published: 2025-01-22T13:06:27+00:00
- Author: Charlotte Edwards

**QuidelOrtho Corporation** with ticker code (QDEL) now have 7 analysts in total
covering the stock. The consensus rating is pointing to ‘buy’. The target price 
High/Low ranges between $64.00 and $38.00 suggesting an average Analsyt target price
of $51.14. Given that the stocks previous close was at $41.74 this now indicates
there is a potential upside of 22.5%. The 50 day MA is $41.86 and the 200 moving
average now moves to $40.92. The market cap for the company is 2.94B. Currently 
the stock stands at: $43.72 USD

 The potential market cap would be $3,602,867,582 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $42.04 and
a 1.04% return on assets.

QuidelOrtho Corporation is a vitro diagnostics company. The Company is engaged in
the development and manufacturing of advanced technologies in diagnostic testing.
Its capabilities include immunoassay and molecular testing, clinical chemistry and
transfusion medicine. The Company’s business units include Labs, Molecular Diagnostics,
Point of Care, and Transfusion Medicine. Its Labs business unit includes Virology,
Specialty Products, Specialty Products, Immunodiagnostics, VITROS Platform, XT Platform,
VITROS XT Platform, and VITROS Automation Solutions. Its Molecular Diagnostics business
includes Lyra, Solana, and Savanna. It provides diagnostic testing solutions under
various brand names, including AdenoPlus, BIOVUE, D, ELVIRA, ELVIS, FastPoint, FreshCells,
InflammaDry, Lyra, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Vision, Quidel,
QuickVue, QuickVue+, QVue, ReadyCells, Savanna, Sofia, Solana, Thyretain, Triage,
Virena, and Vitros.

Share on:
